Charlotte’s Web CEO Sees Healthcare Integration And Industry Alignment Driving The Next Phase Of Cannabinoid Growth

IgniteIt’s Cannabis Capital Conference returns to Chicago on June 15–16, bringing together operators, investors, policymakers, healthcare stakeholders, and entrepreneurs to discuss the future of cannabis and cannabinoids at a pivotal moment for the industry.

Among the executives joining the conversation is Bill Morachnick, CEO of Charlotte’s Web (OTC: CWBHF), one of the most recognizable names in the cannabinoid sector and a company that has helped shape the CBD market for more than a decade.

As cannabinoids move beyond their origins as niche wellness products and attract increasing attention from healthcare providers, researchers, and regulators, Morachnick believes the industry is entering a fundamentally new phase.

From Access Movement To Healthcare Integration

According to Morachnick, the most significant change over the past decade is the growing recognition of cannabinoids within healthcare.

“The biggest shift has been the industry’s evolution from a grassroots movement focused on access to one that is increasingly being recognized within healthcare,” he said.

In the early days of CBD, patients and families often relied on personal experiences and anecdotal evidence when seeking cannabinoid products. Today, the conversation increasingly includes clinical research, physician engagement, and public policy discussions.

Morachnick points to the recent CMS Innovation Center (CMMI) pilot program as an example of that evolution.

“One of the most significant developments is the recent CMS Innovation Center (CMMI) pilot program, which signals a willingness at the federal level to explore established pathways for cannabinoid-based solutions,” he said.

For Charlotte’s Web, that trend reinforces the importance of distinguishing non-intoxicating, science-backed cannabinoid products from broader categories that often become grouped under a single regulatory umbrella.

Where The Next Growth Opportunities May Emerge

As interest grows in wellness, functional cannabinoids, and therapeutic applications, Morachnick sees two major opportunities developing simultaneously.

The first is healthcare integration.

“We see two significant growth opportunities,” he said. “The first is the continued integration of cannabinoid-based therapies into mainstream healthcare, supported by clinical research and growing physician acceptance of plant-based therapeutics.”

Charlotte’s Web has invested heavily in that vision through healthcare practitioner resources and initiatives tied to emerging healthcare programs. The company is also involved in efforts to advance cannabinoid medicine through more traditional pharmaceutical pathways, including its partnership with AJNA BioSciences and DeFloria to pursue FDA-approved botanical drug development.

The second opportunity is occurring in the consumer wellness market.

Morachnick sees growing demand for natural, evidence-based products designed to address everyday concerns such as sleep, stress management, recovery, and overall well-being.

“That demand is driving interest in thoughtfully formulated products that combine cannabinoids with other evidence-based ingredients to deliver measurable benefits,” he said.

Taken together, these two tracks—consumer wellness and pharmaceutical development—represent what Morachnick views as complementary rather than competing opportunities for the industry.

Why The Conversation In Chicago Matters

As the cannabinoid marketplace becomes increasingly diverse, Morachnick believes one of the industry’s biggest challenges is creating a framework that allows multiple product categories to coexist.

He is particularly interested in conversations that bring together leaders from across the cannabinoid ecosystem.

“I’m most looking forward to conversations in Chicago that bring together different segments of the cannabinoid industry, from dietary supplements, beverages, medical, to adult-use, to align on a more collaborative and sustainable path forward,” he said.

Too often, Morachnick argues, policymakers and stakeholders treat all cannabinoid products as a single category despite significant differences in use cases, risk profiles, consumer expectations, and regulatory considerations.

“Each segment has distinct use cases, risk profiles, and consumer expectations, and our policies should reflect that nuance,” he said.

For Morachnick, the future depends on moving beyond industry divisions and toward a more collaborative approach. He will bring that perspective to the Chicago Cannabis Capital Conference on June 15–16, where industry leaders from across the cannabinoid, cannabis, healthcare, and investment sectors will gather to discuss the policies, standards, and market dynamics shaping the industry’s next phase of growth.

“This is a critical moment for the industry to move away from an ‘either/or’ mindset and toward one of coexistence and shared standards,” Morachnick said. “The future credibility and growth of the cannabinoid industry will depend on our ability to present a unified, thoughtful approach to regulators and the public”.

For attendees heading to Chicago, that discussion may prove to be one of the most consequential conversations of the conference.